Lineage Cell Therapeutics (LCTX) Other Gross PP&E Adjustments (2016 - 2025)
Lineage Cell Therapeutics (LCTX) has 15 years of Other Gross PP&E Adjustments data on record, last reported at -$5.9 million in Q4 2025.
- For Q4 2025, Other Gross PP&E Adjustments fell 215.59% year-over-year to -$5.9 million; the TTM value through Dec 2025 reached -$5.9 million, down 215.59%, while the annual FY2025 figure was -$5.9 million, 215.59% down from the prior year.
- Other Gross PP&E Adjustments reached -$5.9 million in Q4 2025 per LCTX's latest filing, down from $2.4 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $3.2 million in Q2 2022 and bottomed at -$5.9 million in Q4 2025.
- Average Other Gross PP&E Adjustments over 5 years is $253526.3, with a median of -$21000.0 recorded in 2023.
- Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 4689.86% in 2022, then plummeted 2638.1% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at $103000.0 in 2021, then tumbled by 2340.78% to -$2.3 million in 2022, then rose by 12.26% to -$2.0 million in 2023, then grew by 8.44% to -$1.9 million in 2024, then crashed by 215.59% to -$5.9 million in 2025.
- Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were -$5.9 million in Q4 2025, $2.4 million in Q3 2025, and $2.8 million in Q2 2025.